此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Comparative Effects of Metformin and Insulin on Stereological Studies and Immunohistochemistry of Placenta

2021年5月28日 更新者:Dr Rabia Arshad、University of Karachi

Comparative Studies of Metformin and Insulin on Stereological Studies and Immunohistochemistry of Placenta

Diabetes mellitus is a group of metabolic disorder characterized by high blood glucose level mainly due to defect in insulin secretion or resistance. In pregnancy, insulin resistance increases as the pregnancy advances, due to the placental hormones predisposing the female to gestational diabetes mellitus (GDM). Placenta is a vital organ as it provides nutrition to the fetus. It shows morphological changes in patients with GDM leading to feto-maternal complications. Insulin, a traditional treatment given for GDM is also known to cause intra uterine deaths, stillbirths and hypoglycemia in mothers and newborns. Insulin being anabolic hormone makes placenta larger in size and causes hypoxic changes with vascular insufficiency, infarctions and hemorrhages. In contrast to this, oral insulin sensitizing drug Metformin, is euglycemic in nature. It has been proven now that Metformin is a vasculo-protective agent, with better patient compliance and beneficial micro-vascular effects in type 2 diabetics. This study was designed to clearly visualize in detail if there are any unrevealed beneficial vascular effects of Metformin on placental tissues and also to compare these effects with Insulin and diet restriction therapy, by doing placental light microscopy, morphometric studies and immunohistochemistry.

研究概览

详细说明

Diabetes mellitus is a group of metabolic disorder with relative or absolute deficiency of insulin. Pregnancy is a potentially glucose intolerant condition as insulin sensitivity decreases with the progress of pregnancy leading to the development of gestational diabetes mellitus (GDM). It is diagnosed in approximately 3-9% of pregnancies and is growing in prevalence. In Pakistan the recent prevalence of GDM is reported to be 3-3.45% but the complications are much higher due to poor glycemic control, lack of awareness and inadequate medical facilities. Placenta is an important feto-maternal organ which is responsible for nutrition of the fetus. It also provides the retrospective information regarding infant's prenatal development. Structurally, human placenta is a complex vascular organ that allows exchange of nutrients and chemicals between fetal and maternal blood. Proper development and maturity of placenta are strongly connected with fetal growth and survival.

GDM produces anatomical and physiological alterations in placenta. This can be related to altered levels of fetal insulin and multiple growth factors such as placental vascular endothelial growth factor (VEGF), Insulin like growth factors (IGF and IGF binding proteins) which regulate the fetal and placental development. Morphologically, diabetic placentae are larger in size and volume. Microscopically, diabetic placenta shows degenerative alternations such as villous fibrinoid necrosis, chorangiosis, villous immaturity, calcification and syncytial knots formation which show intense hypoxia of the placental tissues.

Nutritional therapy (diet control) is foremost important for achieving target glucose values during pregnancy but in uncontrolled cases pharmacological intervention is required. Parental Insulin is the traditional therapy in such circumstances, but is an expensive medication and is associated with high incidence of neonatal and maternal hypoglycemia, still births, neonatal morbidity and mortality. It is documented to produce many placental alterations such as immature villi, hemorrhages, edema, cystic changes and fibrinoid necrosis. It has been postulated that the reason behind all these hypoxic changes are the variation in the blood glucose level that occur in the maternal blood as sugar level suddenly dropped soon after Insulin injection and are at highest just before the next dose of Insulin.

The use of oral anti-diabetic medications such as Metformin in the management of gestational diabetes has increased over the past several years. Recent studies has established that Metformin can be a better option for GDM as it well controls glycemia (produces euglycemic) with good pregnancy outcomes. Metformin is an oral anti-diabetic drug from biguanide group; work by improving insulin sensitivity, reducing hepatic gluconeogenesis and also by increasing peripheral glucose uptake and utilization. It is now been upgraded to category B drug as is not associated with teratogenic effects. But what are the effects of Metformin on stereological morphometric study and immunochemistry of placental tissues were left to be evaluated. Stereology provides practical measurements and significant approach for obtaining quantitative estimates of small structures on histological slides. In placental tissue it is performed to obtain unbiased quantitative estimates of placental components that inform about development and also estimate of structural parameters that have direct influence on placental functional capacity. Immunohistochemistry or immunofluorescence of tissue sections also provide valuable insight to placental structure and protein expression with three-dimensional spatial information, including morphology that cannot be obtained on microscopy.

With this background knowledge, study was designed with the following objectives:

  1. To evaluate the placental gross and microscopic changes in normal, diet control, Metformin and Insulin treated in newly enrolled GDM females
  2. To evaluate stereological morphometric details of placenta in normal, diet control, Metformin and Insulin all enrolled females
  3. To evaluate immunohistochemistry of placental tissues in normal, diet control, Metformin and Insulin in all enrolled females
  4. To compare the placental morphology, stereology and immunohistochemistry with in the groups.
  5. To evaluate the fetal and maternal outcome in normal, diet control, Metformin and Insulin treated gestational diabetics.
  6. To correlate the placental morphology with the fetal and maternal outcome in Metformin and Insulin treated gestational diabetics

研究类型

介入性

注册 (实际的)

156

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Sindh
      • Karachi、Sindh、巴基斯坦、75510
        • Jinnah Post graduate Medical Centre

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 40年 (成人)

接受健康志愿者

不

有资格学习的性别

女性

描述

Inclusion Criteria:

For this study placentae were collected from:

  1. Patients who were diagnosed as GDM during second trimester screening for FBS and RBS, confirmed further by OGCT and OGTT.
  2. GDM patients who signed the written informed consent.
  3. GDM patients who were in ages between 18 years and 40 years and had no other comorbid such hypertension, CVD etc
  4. Full term GDM patients with singleton pregnancy (37 weeks and above)
  5. GDM patients whose placenta were preserved within 30-40 minutes of delivery.

Exclusion Criteria:

Placentae were not collected from:

  1. GDM Patients with ages less than 18 or more than 40 years
  2. GDM females with some co-morbid and complications (e.g. hypertension, CVD, diabetes type 1 or diabetes type 2 before gestation, abnormal Urea Creatinine Electrolyte (UCE) and Liver function test (LFTs).
  3. GDM Patients who delivered pre-termed (< 37 weeks of gestation) or post termed (>42 weeks of gestation)
  4. GDM patients with twin pregnancy.
  5. GDM Patients if not preserved in the formalin properly within 30-40 minutes of delivery.
  6. GDM females who were given combined (Metformin and insulin) therapy.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:其他
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
无干预:Normal healthy controls
females in second trimester with normal glucose levels
无干预:Diet controlled
females in second trimester with blood sugar levels below 129mg/dl
实验性的:Metformin
females in second trimester with blood sugar levels above 130mg/dl treated with Metformin
Euglycemic agent
实验性的:Insulin
females in second trimester with blood sugar levels above 130mg/dl being treated with Insulin
Hypoglycemic agent

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Mean morphometric diffusion capacity for oxygen (MMDC) in placental tissues
大体时间:15 months
With detailed stereological assessment MMDC can be calculated for the placenta to visualize which group placenta allows better diffusion of oxygen
15 months

次要结果测量

结果测量
措施说明
大体时间
Percentage of immuno-antigens present in placental tissue
大体时间:15 months
The percentage of immuno-antigens on the placental tissue is related to the hypoxic and vascular changes in the placenta.
15 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 研究主任:KAUSER AAMIR, Ph.D、BMSI, JPMC,KARACHI

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2018年1月1日

初级完成 (实际的)

2019年2月10日

研究完成 (实际的)

2019年8月7日

研究注册日期

首次提交

2021年5月17日

首先提交符合 QC 标准的

2021年5月28日

首次发布 (实际的)

2021年6月1日

研究记录更新

最后更新发布 (实际的)

2021年6月1日

上次提交的符合 QC 标准的更新

2021年5月28日

最后验证

2021年5月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅